Page 764 - Clinical Hematology_ Theory _ Procedures ( PDFDrive )

748 Index

Erythropoiesis (Continued) diagnosis, 248 Genetic hematopoietic disorders
maturation, 111 FA-B subtype, 248 cancer stem cells, 73–74

metarubricyte, 109, 109 peripheral smear, 248, 249 cell volume homeostasis, 61
prorubricyte, 107–108, 108 therapy, 248–249 cellular membranes
reticulocyte, 109 X-linked recessive, 248t unctions, 59–61
rubriblast, 107, 108 Fast hemoglobins, 128 structure, 59

rubricyte, 108–109, 109 Fc receptor, 178 cellular ultrastructure and organization, 59
erythropoietin, 105–106 Ferritin, 63 cytoplasmic organelles and metabolites, 62–68
maturation, 106, 107 Ferroportin, 124, 265–267 genetic alterations
reticulocytes Fetal hemoglobin (Hb F), 638 hemoglobin S, 72, 72

calculation, 215 laboratory assessment, 235 linkage studies, 73
count, 110 Fibrin ormation assays mutation, 72
Erythropoietin, 92t, 94, 106 D-dimer testing, 538–539, 539 polymorphism, 72
ESR (see Erythrocyte sedimentation rate) brinogen levels, 538 sickle cell trait and anemia, 72

Essential thrombocytosis/essential thrombocythe- reptilase time, 538 single nucleotide polymorphism (SNP), 72
mia (E ), 515 thrombin time, 538 genetic interactions
clinical signs and symptoms, 467 Fibrin split products, 533 alleles, 71
diagnostic characteristics, 466, 466b thrombo-wellcotest method, 697 DNA composition, 71

epidemiology, 466 Fibrinogen gene, 71
karyotype, 466 clotting assay, 697 gene expression and translation, 71
laboratory ndings brin, and actor XIII inhibitors, 568 intron and exon, 71
bone marrow, 467, 467 group, 527 locus, 71

cellular abnormalities, 467 Fibrinolysis, 513, 533, 551 Watson and Crick model, 71
platelet unction, 467 Fibrinolytic hemostasis panel assays, 639, 639b growth processes, reactive and neoplastic,
myeloproli erative disorders, 519 Final common pathway, 529 61–62
pathophysiology, 466 Flame cells, 203 inclusions and metabolites, 63

primary, 381-382 Fletcher actor, 530 minimal residual disease (MRD), 74
thrombocythemia and PRV, 467 Flow cell, 619 molecular diagnostics, 74b
thrombocytosis, 515 Flow cell cytometry, 621 nuclear characteristics
treatment, 467 Flow cytometry activities, 66–68

Esterase, cytochemical staining method, 687–688, applications chromatin, 63–64
688 clinical applications o , 635 chromosomes, 65–66
E (see Essential thrombocytosis/essential general properties o , 634 structure and unction, 63, 64
thrombocythemia) hematological applications, 634 oncogenes, 73

Euchromatin, 63 laser and cell-sort, 634, 634 protooncogenes, 73
Euglobulin lysis time, 696 principles, 621–622, 622 tumor protein, p53, 74
Exomes, 658 Fluid mosaic model, 59, 59 Genome, 65, 653
Exons, 71 Fluorescent in situ hybridization (FISH), 661, Glanzmann thrombasthenia, 520–521

Extramedullary hematopoiesis, 83, 461 662, 663 and essential athrombia, 520
Extravasation, 176 Fluorochromes, 621 Glial cells, 363
Extravascular catabolism, 115 Fluorophore, 621 Globally Harmonized System o Classi cation and
Extravascular hemolysis, 304 Fluorophores, 621 Labeling o Chemicals (GHS), 3

Extrinsic hemolytic anemia, 295 Folate de ciency, 287, 287b Globin gene loci, 126
Extrinsic pathway, 530 Folic acid de ciency anemia Globulin synthesis, 128
Extrinsic system, 492 chemical and immunologic pro le, 287, 288t Glomerulonephritis, chronic, 366
Exudates, 592 etiology, 287 Glucose-6-phosphate dehydrogenase (G6PD),

olates, 287 299–300, 681
F Follicular lymphoma (FL), 429, 429 Glycocalyx, 495
FAB classi cation (see French-American-British Fondaparinux (arixtra), 575 Glycogen, 63
(FAB) classi cation) Forward light scatter (FSC) vs. side light scatter Glycosylated hemoglobin, 128

Factor assays, 696–697 (SSC), 623, 623 Golgi apparatus, 62
Factor de ciency, 536 French-American-British (FAB) classi cation, 372, G6PD (see Glucose-6-phosphate dehydrogenase)
Factor I ( brinogen), 528 373, 382, 383t, 476, 477t Granulation, 98
Factor II (prothrombin), 528 Functional iron de ciency, 230–231, 258 Granules, 495

Factor II, VII, IX, and X inhibitors, 568 azurophilic, 166
Factor IIa (thrombin), 528 G basophilic (see Basophils)
Factor III (tissue thromboplastin), 528 G-bands, 65, 66 67 mast cell, 168
Factor IV (ionized calcium), 528–529 Gametes, 70 neutrophilic (see Neutrophils)

Factor IX (plasma thromboplastin component), Gametocytes, 152 segmented neutrophils, 168, 170t
529 Gametogony, 153 Granulocytes, 97
Factor IX inhibitor, 568 Gastric pathology band orm, 168, 168
Factor V (leiden), 543–544 autoimmune gastritis, 284 basophils

Factor V (proaccelerin), 529 ndings, 284 development, 165, 165
Factor V inhibitor, 568 parietal cell, 284 distribution, 165–166
Factor V R506Q (Leiden), 566 pernicious anemia, 285 granulation, 168–169
Factor VII (proconvertin), 529 Gaucher’s disease, 345, 345 maturation, 165, 165

Factor VIII (antihemophilic actor), 529 Gaussian distribution, 627 maturational characteristics, 165, 166,
Factor VIII inhibitor, 568 Gene rearrangement studies, 654 166–169, 167t
Factor X (stuart actor), 529 Genetic abnormalities and associations, leukemia, mature orms, 168
Factor XI (plasma thromboplastin antecedent), 529 375–376 production, 164–165

Factor XI and XII inhibitors, 568 Genetic and immunological actors, leukemia specialized unctions, 180
Factor XII (hageman actor), 529 chromosomal changes, 373–374 eosinophils
Factor XIII ( brin-stabilizing actor), 530 immunological surveillance, 375 development, 165, 165
Factor XIII de ciency, 557–558 oncogenes, 374 distribution, 165–166

Fanconi anemia protooncogenes, 374, 374t granulation, 168–169
clinical signs and symptoms, 248 tumor-suppressing genes, 374–375 maturation, 165, 165